OCEANIC-Stroke

The following are some additional information with regards to OCEANIC-Stroke:

• The purpose of this study is to learn if asundexian is safe and effective for participants who have had an acute non-cardioembolic ischemic stroke or high-risk TIA on top of background antiplatelet therapy.

• Asundexian (50 mg) vs. placebo

• NIHSS <= 15

Inclusion/Exclusion Criteria: